23:21 , Sep 10, 2018 |  BC Extra  |  Company News

Management tracks: PolarityTE, Medivir

Regenerative biomaterial company PolarityTE Inc. (NASDAQ:COOL) terminated Chief Investment Officer and EVP John Stetson on Friday after the Securities and Exchanges Commission filed charges against him alleging his involvement in "pump-and-dump" schemes (see "Opko's Frost...
23:45 , Aug 21, 2018 |  BC Extra  |  Company News

Management tracks: HBP parts ways with Executive Director Chris Ebell

The Human Brain Project (HBP) said Executive Director and Head of the Project Coordination Office Chris Ebell has resigned "following a change of university leadership and differences of opinion on governance and on strategic orientations...
22:32 , Aug 16, 2018 |  BC Extra  |  Company News

Management tracks: Achillion, Navidea

Rare disease company Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) hired Anthony Gibney as EVP and CBO. He was managing director and co-head of the biotechnology investment banking team at Leerink Partners. Immunotherapy company Navidea Biopharmaceuticals Inc. (NYSE-A:NAVB;...
22:48 , May 3, 2018 |  BC Extra  |  Company News

Management tracks: Achillion, Sangamo

Rare disease company Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) said CEO Milind Deshpande will step down. He will be succeeded by President and COO Joseph Truitt. Sangamo Therapeutics Inc. (NASDAQ:SGMO) said SVP and CBO Curt Herberts, III...
21:23 , Feb 26, 2018 |  BC Extra  |  Company News

Achillion rises on positive opinion for C3G therapy

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) said EMA's Committee for Orphan Medicinal Products issued a positive opinion recommending Orphan Drug designation for ACH-4471 to treat C3 glomerulopathy. Achillion gained $0.46 (15%) to $3.41 on Monday. ACH-4471 is...
21:49 , Dec 1, 2017 |  BC Week In Review  |  Financial News

J&J exits Achillion, Achillion pockets $50.5M

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) raised $50.5 million through the sale of 18.4 million shares at $2.75 per share by existing stockholder Johnson & Johnson (NYSE:JNJ) in a public offering underwritten by Goldman Sachs & Co....
21:41 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

Achillion reports preliminary data from a Phase II trial of ACH-4471 for C3 glomerulopathy

Achillion Pharmaceuticals Inc. (NASAQ:ACHN) said preliminary data from the first 2 patients in a Phase IIa trial to treat complement 3 (C3) glomerulopathy (C3G) showed ACH-4471 reduced albumin-to-creatinine ratio from baseline to day 17 by...
21:43 , Oct 27, 2017 |  BC Week In Review  |  Company News

Arcturus, JNJ to develop nucleic acids to treat HBV

Arcturus Therapeutics Inc. (San Diego, Calif.) and the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) partnered to develop and commercialize nucleic acid-based compounds to treat HBV. The companies will use Arcturus' unlocked nucleomonomer...
22:03 , Sep 18, 2017 |  BC Extra  |  Company News

Management tracks: Kamada, Vertex, Addex, Achillion

Orphan disease company Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) said Deputy CEO and CFO Gil Efron will leave at the end of the year. Chaime Orlev will become CFO, effective Jan. 1, 2018. Orlev was CFO...
21:09 , Sep 15, 2017 |  BC Week In Review  |  Company News

J&J drops Achillion HCV deal

Johnson & Johnson (NYSE:JNJ) terminated a 2015 deal with Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) to develop and commercialize HCV therapies, including triplet therapy JNJ-4178 . J&J said it decided to discontinue development of JNJ-4178 “in light...